Trial results

$ANNX — vonaprument

Annexon, Inc. (ANNX) vonaprument: trial results in geographic atrophy (GA), 2026.

Research by Catalyst Intel

The catalyst

"Vonaprument ARCHER II Phase 3 Well-Designed to Demonstrate Clinically Meaningful Vision Protection in GA; Month 15 Primary Endpoint Assessment on Track for Q4 2026"

— Annexon, 8-K filed 2026-11-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

ANNX-VONAPRUMENT-2026

Company

Annexon, Inc.

Kind

Trial results

Indication

geographic atrophy (GA)

Window

2026-10-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.